AbbVie to Acquire Allergan for $63B
Shots:
- AbbVie to acquire Allergan in cash & stock transaction making the total deal value $63B- based on the closing price of AbbVie's common stock of $78.45 on June 24- 2019. The transaction represents a 45% premium to the closing price of shares of Allergan on June 24- 2019
- Allergan shareholders to receive 0.8660 shares in AbbVie and $120.30 in cash for each share in Allergan for a total consideration of $188.24/share of Allergan. The focus of the acquisition is to expand AbbVie’s revenue base with addition of Allergan’s medical aesthetics and ophthalmology portfolio
- Post-acquisition AbbVie’s shareholder will own ~83% of AbbVie and Allergan’s shareholders will own ~17% of AbbVie on a fully diluted basis. The transaction is expected to close in H1’20
Click here to read full press release/ article | Ref: AbbVie | Image: Allergan
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com